Postmenopausal endometrial hyperplasia: role of danazol therapy.
OBJECTIVE
To confirm the effectiveness of danazol in the management of simple or complex endometrial hyperplasia without atypical features, as has been demonstrated previously.


METHODS
Seventy-six patients affected by postmenopausal histologically-confirmed endometrial hyperplasia with uterine bleeding were submitted to danazol therapy at a dose of 400 mg/day for 3 consecutive months.


RESULTS
After cessation of treatment, 82.8% of the patients (63/76 enrolled) showed a conversion of the hyperplasia into atrophic (65.8%), secretory (11.9%) or proliferative (4.2%) endometrium at the histological examination. Uterine bleeding disappeared, during the therapy, in 90% of the responders (59/63).


CONCLUSIONS
Although 17.1% of the women had a persistence of the hyperplasia and 8.4% of the symptom-free women relapsed after 4 months of follow-up, this experience confirms the effectiveness of danazol therapy in hyperplastic endometrial lesions. Nevertheless, a study comparing danazol and progestin therapy is required.
Mariani
L
L
Department of Gynecologic Oncology, Regina Elena Cancer Institute, Rome, Italy.
Sedati
A
A
Giovinazzi
R
R
Sindico
R
R
Atlante
G
G
D000368:Aged; D003613:Danazol / Q000008:administration & dosage*; D004714:Endometrial Hyperplasia / Q000188:drug therapy* / Q000473:pathology; D004717:Endometrium / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause; D012008:Recurrence
D003613:Danazol